Literature DB >> 20810832

Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Ma Victoria F Balagon1, Robert H Gelber, Rodolfo M Abalos, Roland V Cellona.   

Abstract

We evaluated the incidence, severity, and duration of reactional states in 139 multibacillary (MB) leprosy patients in the first 2 years after the completion of the 1 year regimen of multidrug therapy (MDT) currently recommended by the World Health Organization (WHO) and compared those findings with 295 MB leprosy patients treated with the same regimen previously recommended for 2 years. During the first year after the completion of 1 year MDT, patients experienced 1 or more reactional states 27% of the time, the vast majority being lepra type 1 reactions (reversal reactions, RR), whereas patients who received 2 year MDT experienced a reactional state during that time period only 8% of the time (P < 0.001). Furthermore, during the first year after the completion of therapy, and during the first 2 years, both the number of reactional states and reversal reactions were significantly (P < or = 0.004) more frequent, severe, of longer duration, and more commonly associated with neuritis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810832      PMCID: PMC2929063          DOI: 10.4269/ajtmh.2010.09-0586

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  28 in total

Review 1.  Pregnancy and leprosy: a comprehensive literature review.

Authors:  D N Lockwood; H H Sinha
Journal:  Int J Lepr Other Mycobact Dis       Date:  1999-03

2.  Epidermal keratinocyte Ia expression, Langerhans cell hyperplasia and lymphocytic infiltration in skin lesions of leprosy.

Authors:  T H Rea; J Y Shen; R L Modlin
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

Review 3.  The management of leprosy reversal reactions.

Authors:  W J Britton
Journal:  Lepr Rev       Date:  1998-09       Impact factor: 0.537

Review 4.  Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.

Authors:  B Naafs
Journal:  Int J Lepr Other Mycobact Dis       Date:  1996-12

5.  ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors.

Authors:  P Saunderson; S Gebre; P Byass
Journal:  Lepr Rev       Date:  2000-09       Impact factor: 0.537

6.  Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India.

Authors:  D N Lockwood; S Vinayakumar; J N Stanley; K P McAdam; M J Colston
Journal:  Int J Lepr Other Mycobact Dis       Date:  1993-03

7.  High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy.

Authors:  R Manandhar; N Shrestha; C R Butlin; P W Roche
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

8.  Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment.

Authors:  D Little; S Khanolkar-Young; A Coulthart; S Suneetha; D N Lockwood
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor.

Authors:  R L Modlin; F M Hofman; D A Horwitz; L A Husmann; S Gillis; C R Taylor; T H Rea
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

10.  Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.

Authors:  Roland V Cellona; Maria F V Balagon; Eduardo C dela Cruz; Jasmin A Burgos; Rodolfo M Abalos; Gerald P Walsh; Richard Topolski; Robert H Gelber; Douglas S Walsh
Journal:  Int J Lepr Other Mycobact Dis       Date:  2003-12
View more
  12 in total

1.  Mycobacterium leprae induces Schwann cell proliferation and migration in a denervated milieu following intracutaneous excision axotomy in nine-banded armadillos.

Authors:  Gigi J Ebenezer; Maria T Pena; Amrita S Daniel; Richard W Truman; Linda Adams; Malcolm S Duthie; Kelly Wagner; Serena Zampino; Eleanor Tolf; Daniel Tsottles; Michael Polydefkis
Journal:  Exp Neurol       Date:  2022-03-24       Impact factor: 5.620

2.  The DermLep Study I: Results of Prospective Nation-Wide Survey of the Number & Profile of Leprosy Patients seen by Dermatologists in India.

Authors:  P Narasimha Rao; Santoshdev Rathod; Sujai Suneetha; Sunil Dogra; Sunil Kumar Gupta; Rita Vora; Shushruth Kamoji; Swagta Tambe
Journal:  Indian Dermatol Online J       Date:  2020-09-19

3.  Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: Two Randomised, Double Blind, Controlled Pilot Studies in Ethiopia.

Authors:  Saba M Lambert; Shimelis D Nigusse; Digafe T Alembo; Stephen L Walker; Peter G Nicholls; Munir H Idriss; Lawrence K Yamuah; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2016-02-26

4.  Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.

Authors:  Gerson Oliveira Penna; Samira Bührer-Sékula; Lígia Regina Sansigolo Kerr; Mariane Martins de Araújo Stefani; Laura Cunha Rodrigues; Marcelo Grossi de Araújo; Andrea Machado Coelho Ramos; Ana Regina Coelho de Andrade; Maurício Barcelos Costa; Patricia Sammarco Rosa; Heitor de Sá Gonçalves; Rossilene Cruz; Maurício Lima Barreto; Maria Araci de Andrade Pontes; Maria Lúcia Fernandes Penna
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13

5.  In Situ complement activation and T-cell immunity in leprosy spectrum: An immunohistological study on leprosy lesional skin.

Authors:  Nawal Bahia El Idrissi; Anand M Iyer; Valeria Ramaglia; Patricia S Rosa; Cleverson T Soares; Frank Baas; Pranab K Das
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

6.  International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes.

Authors:  Ponnaiah Manickam; Sanjay M Mehendale; Bathyala Nagaraju; Kiran Katoch; Abdul Jamesh; Ramalingam Kutaiyan; Shen Jianping; Shivakumar Mugudalabetta; Vitthal Jadhav; Prabu Rajkumar; Jayasree Padma; Kanagasabai Kaliaperumal; Vijayakumar Pannikar; Padabettu Krishnamurthy; Mohan D Gupte
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

7.  Diagnosis and impact of neuropathic pain in leprosy patients in Nepal after completion of multidrug therapy.

Authors:  Han-Siong Toh; Jeni Maharjan; Ruby Thapa; Kapil Dev Neupane; Mahesh Shah; Suwash Baral; Deanna A Hagge; Indra Bahadur Napit; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2018-07-02

8.  Patterns and determinants of treatment completion and default among newly diagnosed multibacillary leprosy patients: A retrospective cohort study.

Authors:  Veincent Christian F Pepito; Arianna Maever L Amit; Rae Erica D Samontina; Sarah Jane A Abdon; David Norman L Fuentes; Ofelia P Saniel
Journal:  Heliyon       Date:  2021-06-11

Review 9.  A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction.

Authors:  Carlijn G N Voorend; Erik B Post
Journal:  PLoS Negl Trop Dis       Date:  2013-10-03

10.  Viral Co-infection and Leprosy Outcomes: A Cohort Study.

Authors:  Paulo R L Machado; Lídia M Machado; Mayume Shibuya; Jamile Rego; Warren D Johnson; Marshall J Glesby
Journal:  PLoS Negl Trop Dis       Date:  2015-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.